Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Product Liability Forecast: More Suits, Smaller Scale

This article was originally published in RPM Report

Executive Summary

More than 20 drugs are the subject of multidistrict product liability litigation, but none of the pending cases approach the scope of past lawsuits against Merck’s Vioxx and Lilly’s Zyprexa. That may be one silver lining for Big Pharma as the blockbuster era draws to a close.

You may also be interested in...



US FDA Takes Star Turn In Recent Drug Ingredient Liability Lawsuits

Agency’s direct involvement in pharma product liability litigation is one of the most striking developments in the field over the past year; 16 cases in multidistrict litigation listed in chart showing status of settlements and upcoming bellwether trials.

US FDA Takes Star Turn In Recent Product Liability Lawsuits

Agency’s direct involvement in pharma product liability litigation is one of the most striking developments in the field over the past year. Chart of 16 cases in multidistrict litigation shows status of settlements and upcoming bellwether trials.

After 5-Year Winning Streak, Xarelto Makers Settle Personal Injury Suits

Bayer and Johnson & Johnson agree to resolve approximately 25,000 claims in federal and state courts for $775m, almost 13% of Xarelto's 2018 sales.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel